Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
03:18pm, Thursday, 26'th Feb 2026
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now
10:56am, Thursday, 26'th Feb 2026
Gossamer Bio (GOSS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 26'th Feb 2026
Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
04:25pm, Monday, 23'rd Feb 2026
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%
12:40pm, Monday, 23'rd Feb 2026
Block & Leviton is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) for potential securities fraud. Investors should contact the firm to recover losses.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Gossamer Bio, Inc. (NASDAQ: GOSS). The investigation focuses on Gossamer's
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks
09:57am, Monday, 23'rd Feb 2026
Gossamer Bio Inc. (NASDAQ: GOSS) dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertensio
Gossamer Bio's experimental lung condition drug fails in late-stage trial
08:11am, Monday, 23'rd Feb 2026
Gossamer Bio said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition.
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
08:00am, Monday, 23'rd Feb 2026
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypert
Stock Traders Purchase High Volume of Gossamer Bio Put Options (NASDAQ:GOSS)
03:39am, Friday, 20'th Feb 2026
Gossamer Bio, Inc. (NASDAQ: GOSS - Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders acquired 48,840 put options on the stock. This represents an incr
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of “Moderate Buy” from Brokerages
04:46am, Saturday, 07'th Feb 2026
Shares of Gossamer Bio, Inc. (NASDAQ: GOSS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven analysts that are presently covering the stock, Marketbeat Rating
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)
01:36am, Friday, 06'th Feb 2026
Gossamer Bio, Inc. (NASDAQ: GOSS - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders purchased 32,685 put options on the company. This is an increase of
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 08'th Jan 2026
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Corient Private Wealth LLC Purchases 302,200 Shares of Gossamer Bio, Inc. $GOSS
03:34am, Sunday, 21'st Dec 2025
Corient Private Wealth LLC grew its holdings in Gossamer Bio, Inc. (NASDAQ: GOSS) by 8.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)
01:29am, Tuesday, 16'th Dec 2025
Gossamer Bio, Inc. (NASDAQ: GOSS - Get Free Report) was the target of unusually large options trading activity on Monday. Investors purchased 23,621 call options on the stock. This represents an incre
